Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- B. Neuschwander‐Tetri, R. Loomba, E. Doo
- MedicineThe Lancet
- 14 March 2015
The global NAFLD epidemic
The similarities and differences in the epidemiology of NAFLD in different regions of the world are discussed and the potential role of genetics and insulin resistance in disease progression is also presented.
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- C. Estes, H. Razavi, R. Loomba, Z. Younossi, A. Sanyal
- MedicineHepatology
- 1 December 2017
With continued high rates of adult obesity and DM along with an aging population, NAFLD‐related liver disease and mortality will increase in the United States and strategies to slow the growth ofNAFLD cases and therapeutic options are necessary to mitigate disease burden.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
- P. Dulai, Siddharth Singh, R. Loomba
- MedicineHepatology
- 1 May 2017
The risk of liver‐related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another.
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
- L. Castéra, M. Friedrich-Rust, R. Loomba
- MedicineGastroenterology
- 1 April 2019
The current state of the noninvasive assessment of liver disease in NAFLD is summarized, and an expert synthesis of how these nonin invasive tools could be utilized in clinical practice is provided.
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.
- R. Loomba, V. Seguritan, K. Nelson
- MedicineCell Metabolism
- 2 May 2017
The gut–liver axis and the intersection with the microbiome
- A. Tripathi, J. Debelius, R. Knight
- Medicine, BiologyNature reviews: Gastroenterology & hepatology
- 10 May 2018
Gut–liver communications in liver disease is reviewed, exploring the molecular, genetic and microbiome relationships and discussing prospects for exploiting the microbiome to determine liver disease stage and to predict the effects of pharmaceutical, dietary and other interventions at a population and individual level.
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
- Daniel Q. Huang, H. El‐Serag, R. Loomba
- Medicine, BiologyNature reviews: Gastroenterology & hepatology
- 21 December 2020
Urgent measures that increase global awareness and tackle the metabolic risk factors are necessary to reduce the impending burden of NAFLD-related HCC and propose preventive strategies to tackle this growing problem.
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
- R. Loomba, M. Abraham, N. Bass
- MedicineHepatology
- 1 September 2012
Family history of diabetes, especially among nondiabetics, is associated with NASH and fibrosis in NAFLD, and diabetes is strongly associated with risk of NASH, fibrosis, and advanced fibrosis.
...
...